Zhitong Finance App News, Jingfang Pharmaceutical-B (02595.HK) issued an announcement. GFH375/VS-7375 (oral KRAS G12D inhibitor) has made positive progress in several domestic and overseas clinical studies and released the latest data on related studies. Currently, GFH375 has obtained three breakthrough therapy certifications (BTD) for treating KRAS G12D mutant pancreatic cancer, non-small cell lung cancer (NSCLC), and colorectal cancer (CRC) in China, and has entered two registered phase III studies for single-drug treatment of pancreatic cancer and NSCLC. At the end of this year, Jingfang's overseas partner Verastem Oncology (Verastem) is expected to launch a registered phase III study of VS-7375 multiple combination programs (combined with anti-EGFR therapy or chemotherapy) for first-line PDAC treatment, with progression-free survival (PFS) and objective response rate (ORR) as the two main endpoints and overall survival (OS) as the secondary end point. A consensus has now been reached with the US Food and Drug Administration (FDA) on the research plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.